3h agoThe FlyBEARISH 34Analyst
Why Is OPPENHEIMER HLDGS IN A (OPY) Stock Down Today?
By the Top Tier Newswire AI Desk · reviewed against 5 wire stories
OPPENHEIMER HLDGS IN A (OPY) is down -5.48% in the latest session. Our newswire has captured 5 stories on OPY across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 43/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for OPY publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
OPY by the numbers
Last: $112.64Session: -5.48%7 sessions: -8.96%Coverage: 5 stories / 4 sourcesAI sentiment: 43/100 (mixed)
The headlines behind the move
3h agoBusiness InsiderBULLISH 55General
Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase
SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D.
21h agoCNBCNEUTRAL 50Analyst
The near term remains very uncertain for Nike, says Oppenheimer's Brian Nagel
1d agoThe FlyBEARISH 34Analyst
Boston Scientific price target lowered to $65 from $85 at Oppenheimer
1d agoYahoo TopBEARISH 42Analyst
Analyst: Meta Needs Just 115 Million Users to Ignite a $28 Billion AI Gold Rush — But It’s Not Likely to Happen
Jason Helfstein, Oppenheimer’s Managing Director and Senior Analyst covering the Internet sector, laid out a striking scenario in a September 2026 note: Meta Platforms (NASDAQ:META) would need roughly 115 million paying Muse subscribers at a $20/month price point to generate about $27.5 to $28 billion in annual AI agent revenue. His conclusion, however, was skeptical. […]
Frequently asked questions
Why is OPY stock down today?
OPPENHEIMER HLDGS IN A (OPY) is down -5.48% in the latest session. Our newswire has captured 5 stories on OPY across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 43/100). The most recent driver: "Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer" (The Fly).
Is OPY a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of OPY coverage reads 43/100 over 5 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is VKTX up today (+24.84%)
- Why is BFLY up today (+18.67%)
- Why is CLDX down today (-13.54%)
- Why is VICR up today (+12.65%)
- Why is ONON up today (+11.09%)
- Why is CPRI up today (+9.19%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on OPY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.